Finite or infinite ordered list of elements
POPULARITY
Categories
92 episodes with sequential
38 episodes with sequential
19 episodes with sequential
44 episodes with sequential
23 episodes with sequential
21 episodes with sequential
21 episodes with sequential
18 episodes with sequential
25 episodes with sequential
18 episodes with sequential
21 episodes with sequential
6 episodes with sequential
4 episodes with sequential
3 episodes with sequential
3 episodes with sequential
2 episodes with sequential
3 episodes with sequential
2 episodes with sequential
5 episodes with sequential
4 episodes with sequential
6 episodes with sequential
6 episodes with sequential
3 episodes with sequential
2 episodes with sequential
3 episodes with sequential
2 episodes with sequential
2 episodes with sequential
Empathy is pioneering bereavement care as an enterprise benefit, transforming how employers and financial institutions support employees during life's most challenging transitions. Working with 9 of the top 10 life insurance carriers in the US and Canada—covering over 40 million people—Empathy created a new category by combining grief support with practical logistics like probate navigation, account deactivation, and estate settlement. In a recent episode of BUILDERS, we sat down with Ron Gura, Co-Founder & CEO of Empathy, to learn how the company went from testing five verticals simultaneously to dominating life insurance, then leveraged the group life/employer overlap to expand into employee benefits. Topics Discussed: Testing five enterprise verticals simultaneously to find product-market fit Landing New York Life through their venture arm and innovation team Why life insurance carriers need to be risk-averse (and how to work with that reality) The strategic overlap between group life insurance and employee benefits Investing in brand at seed stage when your barrier to entry is psychological aversion Navigating dual audiences: decision-makers in their workday versus end users in crisis Expanding from loss to adjacent life transitions like disability leave and estate planning GTM Lessons For B2B Founders: Run parallel vertical tests with focus constraints, not sequential exploration: Ron identified 10+ potential verticals but intentionally tested exactly five simultaneously—hospices, funeral homes, employers, and two others before life insurance emerged as the winner at position five. This parallel testing with artificial constraints forces prioritization while dramatically compressing time-to-insight. Sequential testing would have meant potentially cycling through five failed pilots before discovering their strongest market. B2B founders with horizontal platforms should pick their top 3-5 verticals and run focused pilots in parallel, accepting that this burns more resources upfront but eliminates the risk of quitting before finding your wedge. Map the ecosystem overlap between buyer personas before choosing your wedge: Empathy's expansion from life insurance to employers wasn't growth strategy—it was recognizing an architectural reality. Half their carriers sell group life, meaning MetLife doesn't sell to consumers at metlife.com but exclusively to employer groups. When Amanda at Paramount loses her sister (not covered by insurance), she calls Paramount HR. When her husband dies (covered by MetLife group policy), the beneficiary calls MetLife. Same end user, two different enterprise entry points into the same moment. B2B founders should map these triangular relationships before choosing their wedge vertical. The question isn't just "who has budget?" but "who else touches this user in adjacent contexts?" Brand investment at seed stage is product strategy when fighting cognitive aversion: Ron's insight: "The barrier to entry isn't regulatory and isn't technology. It's us humans trying really hard not to think about our own mortality." This isn't a marketing problem—it's a fundamental go-to-market blocker. The company made what most would consider Series A investments (premium domain, design system, tone/voice framework) at seed stage specifically because brand reduces psychological friction to adoption. Contrast this with Monday.com starting as "daPulse" and rebranding years into success. B2B founders addressing taboo topics (death, mental health, financial distress, relationship issues) should model brand as a core distribution lever, not post-PMF polish. In deeply human categories, buyer's lived experience is your demo: Enterprise buyers at Citibank, MetLife, or Google aren't experiencing crisis during the sales cycle—they're evaluating ROI in their normal workday. But as Ron noted, "Everyone we're talking to...they're humans. They have parents, they had loss, they went through probate." The most common response after seeing the product: "Damn, I wish you called me a few months ago. I needed this a year ago with my mom." This turns product demo into personal recognition. B2B founders in universal human experience categories (caregiving, bereavement, parental leave, financial stress) should structure discovery and demo to activate buyer's memory of their own experience, not just their budget authority. Category creation is a resource-attraction strategy that trades speed for competitive exposure: Ron explicitly acknowledged: "There's pros and cons to defining a category. It's helpful when you attract resources, talent, capital. It also creates very fertile ground for a number two sympathy.com to come along and learn from this podcast...what to go after." Category leadership accelerates recruiting and fundraising by providing narrative clarity, but it simultaneously publishes your playbook. Every hiring blog post, podcast appearance, and positioning document teaches future competitors which verticals to target and which to avoid. B2B founders should treat category creation as a conscious bet: trade competitive opacity for talent/capital velocity. If you're not ready to defend your position, stay in stealth longer. Bridge new categories to existing budget lines through analogous benefits: When entering new verticals beyond life insurance, Ron doesn't educate from zero. With employers, he positions bereavement care alongside caregiving solutions, fertility programs, and parental leave: "This is a life transition happening in my own intimate house. Just like a new baby. I have new duties now." This isn't metaphor—it's budget mapping. Bereavement care gets evaluated against existing family benefits spending, not created from scratch. B2B founders in new categories should identify which existing line item their solution logically extends, then structure ROI narratives around reallocation, not net-new budget creation. // Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe. www.GlobalTalent.co // Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM
How early in process development should you address glycosylation? This episode presents the case for co-optimizing glycan profiles with productivity from initial process characterization. Deferring glycosylation characterization until after titer targets are met introduces risk: quality attribute gaps discovered late in development force process re-optimization, extended timelines, and potential cell line reselection. Media supplementation enables earlier intervention—tuning glycan distribution as a process parameter from the beginning of cell line and media development rather than as a remediation strategy.David Brühlmann outlines the experimental protocol for validating raffinose supplementation, including decision criteria for proceeding or terminating at each development stage. The discussion addresses process design space requirements, analytical monitoring strategy, and the experimental variables that determine when media-based glycan tuning is appropriate versus when alternative approaches are needed.Highlights from the episode:When to use (and not use) raffinose in your development program, including limitations and effectiveness windows (00:30)Essential protocol: three experiments over eight weeks to validate raffinose for your process, with clear go/no-go criteria (04:09)Why individualized mannose tracking (Man5, Man6, Man7, Man8) is crucial for meaningful results (01:06)Managing osmolality: why it matters and how to control it in your experiment (04:36)Advice on scaling up: moving from small-scale screens to benchtop bioreactors and stress-testing your process (07:48)Three key mistakes to avoid when implementing raffinose, including lessons from analytical oversight, incomplete design mapping, and feed interference (09:08)Integrating glycosylation as a core part of process design, not just a secondary consideration after titer optimization (13:10)Strategic insight:Sequential optimization of productivity followed by glycosylation introduces development risk: quality attribute deviations discovered after process lockdown require costly re-optimization cycles. Parallel development of titer and glycan specifications from initial cell line characterization reduces this risk by establishing feasible operating windows early in the development timeline.Are you planning your next recombinant protein scale-up? Hear how David's rule-of-three protocol and battle-tested lessons can help you optimize faster and avoid painful late-stage surprises.Resources: Journal of Biotechnology, 2017, volume 252, pages 32 to 42Next step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
Let me start with a confession. Classifiers are hard. Not hard in the way vocabulary is hard, where you simply need more exposure, more repetition, more time. Classifiers are hard because they require signers to think spatially while signing temporally, to track multiple referents while producing new content, to select among productive options while maintaining discourse coherence. That mouthful of a sentence appears in the opening of Depicting Space, and I want to unpack it for you, because hidden inside that description is something important about human cognition. When you speak English, your words unfold in time. One after another. Linear. Sequential. The sentence has a beginning, a middle, an end. You cannot say two words simultaneously. The channel is narrow. But when you sign ASL, something different happens. Your hands can represent two entities at once. Your face carries grammatical information independent of your hands. Your body can shift to become a character while your hands continue to manipulate objects in observer space. The channel is wide. Parallel processing becomes possible.
In this solo episode of Building Better, I explore a pattern I see everywhere. In engineering, in leadership, and in life.Most systems are built sequentially. One decision at a time. One optimization at a time. One fix after another. That approach works. It is safe. It prevents disasters.But it rarely produces truly great outcomes.Using product development and APQP as a starting point, I contrast sequential design with parallel processing. Learning late versus pulling understanding forward. Optimizing parts versus optimizing the system.I then zoom out beyond engineering to show how the same pattern shows up in home projects, health, parenting, and how we design our lives and organizations.This episode is about capability, foresight, and the difference between reacting your way to “good enough” and designing for something better from the start.Music creditSlow Burn by Kevin MacLeod
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PWK865. CME/MOC/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Next-Gen Advances for Upfront and Sequential Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/JGX865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical educational grants from Arcellx, Inc. and Kite, a Gilead Company; GSK; Johnson & Johnson; and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/JGX865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical educational grants from Arcellx, Inc. and Kite, a Gilead Company; GSK; Johnson & Johnson; and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PWK865. CME/MOC/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Next-Gen Advances for Upfront and Sequential Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/JGX865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical educational grants from Arcellx, Inc. and Kite, a Gilead Company; GSK; Johnson & Johnson; and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PWK865. CME/MOC/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Next-Gen Advances for Upfront and Sequential Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/JGX865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical educational grants from Arcellx, Inc. and Kite, a Gilead Company; GSK; Johnson & Johnson; and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PWK865. CME/MOC/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Next-Gen Advances for Upfront and Sequential Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/JGX865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical educational grants from Arcellx, Inc. and Kite, a Gilead Company; GSK; Johnson & Johnson; and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PWK865. CME/MOC/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Next-Gen Advances for Upfront and Sequential Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PWK865. CME/MOC/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Next-Gen Advances for Upfront and Sequential Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/JGX865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA Immunotherapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical educational grants from Arcellx, Inc. and Kite, a Gilead Company; GSK; Johnson & Johnson; and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
In this episode, newcomer to the show Victoria Hutton of 39 Essex Chambers considers the recent Planning Practice Guidance changes and how the sequential test is affecting development. The sequential test is a process used to assess flood risk by comparing a proposed development site with other available sites to ensure it is located in an area with the lowest risk of flooding. Featuring ducks and puddles!This is a series of specials from the inaugural Have We Got Planning News For You Live Conference, which took place at The Honourable Society of the Inner Temple in London. We will have a new episode every weekday right up until the publication of the new revised NPPF (which may or may not release around the 18th of December...).Donate to the Child Poverty Action Group.Conference resources can be found on our website here.Have We Got Planning News for You is a light-hearted review of the month's latest developments by six barristers from across the Planning Bar: Paul Tucker KC, Thea Osmund-Smith, Sasha White KC, Charlie Banner KC, Victoria Hutton and Christopher Young KC.The views expressed by our guests are their own and do not necessarily represent the views of the panellists.#HWGPNFY #HWGPNFYlive25
Beijing's Sequential Strategy to Break the Coalition: Colleague Elbridge Colby explains that Beijing has abandoned "hide and bide" for a focused and sequential strategy designed to dismantle the anti-hegemonic coalition, targeting vulnerable US partners to demonstrate American hollowness, hoping to erode regional confidence and achieve dominance without fighting a total, catastrophic war.
Building a $2.5 million portfolio is hard. Spending it without running out? That's even harder. Welcome to the 700th episode of the BiggerPockets Money Podcast! To mark this milestone, hosts Mindy Jensen and Scott Trench are tackling one of the most critical—and most overlooked—aspects of financial independence: decumulation. Most people obsess over building wealth but stumble when it's time to actually spend it. The withdrawal strategy you choose can mean the difference between a comfortable 40-year retirement and running out of money at the worst possible time. In this episode, we cover: Sequential vs. blended vs. cyclical withdrawal strategies—which is right for you? How to create a tax-efficient drawdown plan that could save you hundreds of thousands The role of Roth accounts, traditional IRAs, and taxable brokerage accounts in your withdrawal strategy When to do Roth conversions and how to time them for maximum benefit Healthcare planning in early retirement and how it affects your withdrawal strategy Estate planning considerations and maximizing what you leave behind Real-world scenarios: what withdrawal strategies look like in practice The biggest mistakes retirees make in the decumulation phase Whether you're just starting your FI journey or you're ready to retire next year, this comprehensive guide will help you spend your money strategically, minimize taxes, and make your nest egg last. Learn more about your ad choices. Visit megaphone.fm/adchoices
"Eliminate frustration and speed ahead." Who doesn't want this? When it comes to strength training - and calisthenics in particular - many ambitious and well-meaning enthusiasts jump right into a laundry list of progressions... And fall flat on their tushes. If you want to feel like you're positively speeding through the various and sundry progressions that lay at the heart of each and every advanced calisthenics movement, you must first dominate their prerequisite movements. This is the sure-fire path to things such as: One-arm pushups Pistol squats Nigh on effortless pullups much, much more In this episode I dish on: [0:00:28] Natural Movement and Standardized Exercises Discussion about learning basic movement patterns, balancing standardized exercises with natural human movements, and recommendations such as crawling, carries, and gait pattern work. [0:02:36] Handstand & Prerequisite Example from Social Media [0:05:00] Personal Anecdote: Prerequisites in Practice [0:06:27] Progress with Handstands and Sequential vs. Simultaneous Training [0:09:16] Lunge Program Leading to Improved Pistol Squats [0:10:32] Embracing the Foundations Valuing foundational, repetitive practice (particularly of prerequisites) across fitness skills. [0:11:06] Closing If you like training that: · Gives you more strength than it takes from you · Improves your stamina and resilience simultaneously · Powers-up every nook, cranny, crevice, and corner of your Soft Machine Then you just might like my 9-Minute Kettlebell and Bodyweight Challenge. As the name indicates, it's just 9 minutes long, and it's designed to be done WITH your current workouts – NOT instead of them. Even cooler: Many find that it actually amplifies their strength in their favorite kettlebell and bodyweight moves, like presses, squats, pullups, and more. And best of all, it's free. How free? I'm talkin' freer than the 4th of July, my friend. Get thee thine own copy here: http://www.9MinuteChallenge.com Have fun and happy training! Aleks Salkin
Are you using the wrong retirement withdrawal strategy? Sequential drawdown—draining one account before touching the next—is the most common approach to early retirement, but it could be costing you tens of thousands in unnecessary taxes. In this episode of the BiggerPockets Money Podcast, hosts Mindy Jensen and Scott Trench sit down with Enrolled Agent Mark to break down tax-efficient withdrawal strategies that maximize your retirement savings. Discover blended drawdown strategies and cyclical drawdown methods that optimize which accounts you tap first—Traditional IRA, Roth IRA, taxable brokerage, HSA—to minimize your lifetime tax burden. This episode covers: Sequential vs. blended vs. cyclical retirement drawdown strategies How to optimize withdrawal order from retirement accounts (401k, IRA, Roth, taxable accounts) Tax-efficient retirement planning for early retirees and FIRE followers How to leverage today's historically low tax rates before they expire Healthcare costs in early retirement (ACA subsidies, Medicare planning) Asset protection and estate planning considerations Roth conversion strategies during low-income years How to avoid costly tax mistakes in the decumulation phase Whether you're planning for financial independence, already retired early, or managing multiple retirement accounts, this tax optimization masterclass will help you keep more of your money and make your nest egg last longer. Learn more about your ad choices. Visit megaphone.fm/adchoices
Peter Jones, who heads up Revenue at Premion, returns to Insider Interviews (see Ep 38) to educate us on the shifts in local TV advertising in a streaming-first world -- and how small businesses can compete with national brands, with greater access to sports inventory, and why measurement actually matters! Learn what "context" really means for advertisers (spoiler: consumers don't experience media in silos), how the collapse of some Regional Sports Networks has created opportunities for local advertisers, and why "smart curation" is more than an industry buzzword. But it's not just the small business that needs to adapt: it's agencies and brands, too. Peter breaks down what full-funnel capabilities now available to SMBs—from maxing out brand awareness across Premion's 210 DMAs, to measurable sales transactions, tapping 1st and 3rd party data. And, as we gear up for playoff sports, he reminds us how technology has leveled the playing field and that local advertisers can get in the game, too! So, sports puns are pervasive in Episode 44 since part of our conversation is about Premion's new(ish) programmatic options to enable more inventory for all in live sports. Talk about a “game changer...!” Understand how local car dealerships and furniture stores can now leverage the same targeting, data, and attribution tools that Fortune 500 companies use, all while reaching their specific communities with precision. But for everyone, it's key to understand the importance of creative in driving outcomes, and omnichannel strategies (because yes, we're all scrolling during halftime), and why advertisers need to embrace data-driven decisions over personal platform preferences. "The first thing to realize is that big tech has leveled the playing field for local advertisers..." Whether you're a media buyer, agency leader, or local business owner trying to navigate the CTV landscape, this conversation delivers practical guidance on inventory, data, and measurement—the three pillars every advertiser should evaluate when choosing a CTV partner. Bottom line? The local advertising opportunity in streaming TV has never been bigger—but only for those willing to adapt, measure outcomes over impressions, and follow consumers wherever they are. Key Highlights [01:15] CTV's double-digit growth, challenges and opportunities for advertisers [02:14] What Premion does – Nine years of helping local advertisers navigate CTV [03:33] Leveling the playing field – Educating SMBs on using the same tools as national brands [05:25] Challenges and Strategies for Outcomes in Omnichannel Advertising [08:26] Tools and tactics – First-party data, pixels, attribution, and what SMBs need to track [10:48] The role of creative – Sequential messaging, AI tools, and "message to market match" [12:52] How Premion's programmatic access to sports inventory is opening doors for local advertisers [15:39] Smart Curation Explained and Full Funnel Options in 200+ markets [20:22] The dynamic nature of live sports – Why planning can be tricky but opportunity is massive [21:45] What to look for in a CTV partner – Hint: Inventory, data, measurement (plus the TAG seal of approval!) [23:41] Emerging Trends and AI in Advertising Connect with Peter Jones and Premion Connect with E.B. Moss and Insider Interviews: With Media & Marketing Experts LinkedIn: https://www.linkedin.com/in/mossappeal Instagram: https://www.instagram.com/insiderinterviews Facebook: https://www.facebook.com/InsiderInterviewsPodcast/ Threads: https://www.threads.net/@insiderinterviews If you enjoyed this episode, follow Insider Interviews, share with another smart business leader, and leave a comment on @Apple or @Spotify… or a tip in my jar!: https://buymeacoffee.com/mossappeal!
Program notes:0:40 CVD risk factors and texting1:40 How many undergo screening?2:41 Impact of personalized messaging3:25 Decentralized trials versus centralized 4:25 Decentralized much larger5:25 Does the trial move in one way or another?6:15 Two studies related to use of peripregnancy GLP-1 use7:15 Stopping at pregnancy8:15 Is overweight worse than stopping?9:00 Machine learning model, tissues, genetics and age10:00 Practical for assessing genetic basis11:00 Sequential tissue samples11:57 End
Drs. Lewiecki and Camacho discuss sequential therapy in osteoporosis as a critical strategy that involves strategically switching between anabolic and antiresorptive treatments to maximize bone mineral density and reduce fracture risk. By carefully transitioning between different drug classes (eg, romosozumab; teriparatide; denosumab), clinicians can optimize patient outcomes and address the evolving needs of individuals with bone health challenges.
Matthew Cassidy of Partners Wealth Group has just taken the top spot in this year's Barron's Top 150 Advisers List. He offers a unique perspective on what you need to know about advice, and how to deal with an investment market that is clearly at the top of the cycle. Matthew Cassidy of Partners Wealth Group joins Associate Editor - Wealth, James Kirby in this episode. In today's show, we cover: What you should expect from a top financial adviser How to prepare for a sharemarket downturn Sequential risk - The biggest financial threat to the pre-retiree Taking profits off the table See omnystudio.com/listener for privacy information.
Creepy Adaptations: In a belated Halloween episode of Panel Borders, Alex Fitch talks to a trio of creators about their work on creepy adaptations. Graphic novelist, Lucy Sullivan, and film director, Dylan Southern, have worked together on The Thing With Feathers, an adaptation to screen of Max Porter’s award-winning 2015 novella. Lucy has created new […]
The full story behind our 2025 Grid Life Street Mod Championship season. After the struggles of 2024, we came back with a vengeance - 8 events, 5 straight wins, 7 lap records, and the most reliable car in Street Mod.In this extended season recap, Dewey, Dylan, Graham (Boosted Performance Tuning), and Forklift break down everything that happened behind the scenes: building our first sequential transmission, solving the turbo issues at Road Atlanta, the data analysis systems that changed everything, and that incredible rain-soaked victory at Pitt Race.Topics covered:Sequential transmission development and tuning challengesEvery event breakdown from CMP to Pitt RaceTechnical upgrades: suspension geometry, power steering, front diffThe criticism we faced and how we proved everyone wrongBehind-the-scenes logistics and team dynamicsOur systematic approach to data analysis and driver feedbackPlans for 2026: electronic wastegate, motorsport ABS, and morePlus: Terrible steak dinners in castles with Bucky Lasek, windshield explosions, trailer disasters, and why 38°F is the perfect temperature for Pitt Race.This isn't just about winning - it's about the work, the team, and the process that made it possible.#GridLife #TimeAttack #StreetMod #Subaru #Championship #Motorsports
SOFA-2, validated in more than 3 million intensive care unit (ICU) patients, incorporates contemporary organ support treatments, showing strong predictive validity for ICU mortality in diverse international settings. Coauthor Mervyn Singer, MD, joins JAMA Associate Editor Christopher W. Seymour, MD, MSc, to discuss. Related Content: Rationale and Methodological Approach Underlying the Development of the Sequential Organ Failure Assessment (SOFA)–2 Score Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score A Revision to Organ Failure Assessment in Critically Ill Patients
Midjourney Fast Hours — Episode 51: “Sora 2, Veo 3 & The AI Video Gold Rush”Drew and Rory crawl out of their creative caves after a month-long “break” (read: total burnout) and immediately get smacked in the face by Sora 2, Veo 3, and Midjourney Style Explorer updates that make everything they said last episode obsolete.They break down what's actually working in Sora 2 (full edits, audio, dialogue, even IP?), why Veo 3 can't seem to go fast anymore, and how keyframes are quietly becoming the holy grail of AI video.Expect rants about IP chaos, Mr. Rogers cameos, and why OpenAI's guerilla launch strategy might be the smartest marketing move of 2025.It's equal parts therapy session, tech panic, and creative caffeine rush — exactly how they like it.Keywords: Sora 2 update, Google Veo 3 review, Midjourney V8, AI video generation tools, Luma AI, keyframes, AI video editing, AI marketing trends 2025, generative video, Style Explorer Midjourney---⏱️ Midjourney Fast Hour00:00 – Intro + return from creative hibernation00:42 – Sora 2 drops: “the floodgates just opened”01:27 – Sora 2's new tricks: editing, sound, dialogue, and IP02:17 – Veo 3 vs Sora 2 vs Ray 303:20 – Rory's South Park AI episode + the “bar-only” friend05:00 – Why dedicated AI-only spaces actually matter05:48 – Remix culture, Mr. Rogers AI, and the rise of comedic timing07:00 – The “Remix” button, mass adoption, and kids using Sora08:43 – The IP gray area: Minecraft meets Mr. Rogers09:43 – Cameos, access codes, and mobile vs desktop creation12:25 – Sequential storytelling: AI understands chronology now13:29 – Toyota ads, guerrilla launches, and OpenAI's flood strategy15:00 – IP risk vs reward — how far can brands push it18:00 – AI performance comparisons23:00 – Fight scenes, motion control, and why keyframes matter27:50 – Workflow troubleshooting and micro-decision fatigue34:50 – Too many tools? Runway, Aleph, and the Weavy advantage35:45 – Shout-out to Weavy + tool consolidation predictions36:00 – Higgsfield pivots, Pika memes, and the marketing gap37:00 – Visual Electric's acquisition and the coming consolidation wave38:20 – Midjourney updates: Style Explorer, Smart Search, and new unlocks40:30 – Playing with EXP mode + hidden color/style refinements42:30 – Style Finder, Style Creator, and mood-board personalization43:57 – Style ranking feature + --r 40 nostalgia meltdown46:00 – Midjourney V8 speculation & dataset rumors50:30 – Google's product chaos: Gemini, Nano Banana, Flow, and Veo 353:00 – Why Google can fail (and still win)55:10 – ChatGPT's image text features & the next AI video wave59:30 – The Weavy renaissance and workflow automation discussion1:02:00 – New creative problems worth solving1:06:00 – Why “easy” AI creation still stings for creatives1:08:30 – Closing banter + “hit the button” outro
Robaux's serving pie, Teenage Engineering's cooking dub, and Sequential's back with poly aftertouch.
Inspired by the Twentieth Century: Alex Fitch looks at the work of cartoonists influenced by the culture of the Twentieth Century. In a Q and A recorded at the Lakes International Comic Art Festival, artist Juanjo Guarnido discusses his much loved anthropormophic graphic novel series Blacksad, and in a conversation recorded at Cartoon County, Digital […]
Cunningcast is back and Tony is kicking off his new series with one of his favourite subjects, Stonehenge, where new discoveries show that once again this ancient site is throwing up new evidence. Tony has invited his old friend, leading archaeologist Mike Parker Pearson, to discuss the Altar Stone's Scottish origins and its implications for understanding the monument's significance.Also joining the chat is top geologist Jane Evans, whose new research has revealed the fascinating story of an ancient cow's journey from Wales to Stonehenge. Through isotope analysis, Jane has uncovered insights about the Stonehenge cow's diet and origins, leading to broader implications about our ancient communities and their interactions.Hosted by Sir Tony Robinson | Instagram @sirtonyrobinsonProducer: Melissa FitzGerald With Mike Parker Pearson Professor of British Later Prehistory, University College London. He specialises in British and European prehistory from the Neolithic to the Iron Age; Stonehenge and the British Neolithic; the Beaker people of Bronze Age Europe; the archaeology of the Western Isles (Outer Hebrides); the archaeology of Madagascar and the Indian Ocean; the archaeology of death and burial; public archaeology and heritage. Parker Pearson, M. 2023. Stonehenge: a brief history. London: Bloomsbury Publishing | https://www.bloomsburycollections.com/monograph?docid=b-9781350192263 Parker Pearson, M., Bevins, R.I., Bradley, R., Ixer, R.E., Pearce, N.J.G. and Richards, C. 2024. ‘Stonehenge and its Altar Stone: the significance of distant stone sources'. Archaeology International 27: 113–37 | https://journals.uclpress.co.uk/ai/article/id/3293/ Professor Jane Evans Geologist whose early career focused on using isotope methods for dating rocks. She later turned her expertise toward archaeology, pioneering the use of isotopes to study past human migration. Now retired, she holds honorary professorships in archaeology at the Universities of Nottingham and Leicester and is an Honorary Research Associate at the British Geological Survey. Throughout her career, Jane has used the chemical signatures preserved in human remains to reveal where people came from and how they moved across landscapes. Her work has been central to major discoveries — from uncovering stories at Stonehenge and identifying Viking remains near Weymouth, to contributing to the investigation of King Richard III. Evans, J., Pashley, V., Wagner, D., Savickaite, K., Buckley, M., Madgwick, R. and Parker Pearson, M. In press. Sequential multi-isotope sampling through a Bos taurus tooth to assess comparative sources in strontium and lead. Journal of Archaeological Science | https://www.sciencedirect.com/science/article/pii/S0305440325001189Follow us:Instagram @cunningcastpod | X @cunningcastpod | YouTube @cunningcast Hosted on Acast. See acast.com/privacy for more information.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WMD865. CME credit will be available until August 20, 2026.At the Nexus of Sequential Care in Myeloma: Interprofessional and Patient Perspectives on GPRC5D-Directed Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
Comic Book Team-Ups: Alex Fitch talks to a trio of creators about their collaborative work. Matt Wakeham discusses writing and compiling the new coffee table book of Phoo Action, a cult comic by Jamie Hewlett that Wakeham wrote the second series of and adapted for television, which was originally serialised in The Face magazine. And […]
As an independent musician, diving into the world of MIDI controllers and studio gear can feel intimidating, especially if you're unsure where to start or which tools best suit your creative process. In this episode, Xylo chats with Alex Godfrey, Product Specialist at the Focusrite Group, about what MIDI controllers actually are, how they work, and how to choose the right one for your music.With over 10 years at Focusrite and hands-on experience representing brands like Novation, Sequential, Oberheim, Focusrite, Adam Audio, and Sonnox, Alex breaks down the essentials of MIDI technology in a clear and practical way. From testing music tech as part of Focusrite's QA Engineering team to producing experimental tracks as Psychedalex, he brings both technical expertise and creative insight. Whether you're just setting up your first home studio or looking to expand your gear, this conversation will help you make confident, informed choices.Distrokid has kindly offered all MPW listeners a 30% discount off the first year of their annual subscription! Use the following link to redeem the discount: http://distrokid.com/vip/mpw
Clay Stephens of 6XD Gearbox joins us to teach us a bit about their product, sequential transmissions, the creation of the 6XD standard gearbox, the XTD gearbox, and the MTX transaxle. In addition to a bit about himself as well. High Performance Academy: https://hpcdmy.co/Minnoxide Use code "MINNOX" for 55% off ANY course Use Code "MINVIP" for $300 of the MINVIP Package Tuned By Shawn: https://www.tunedbyshawn.com Code "Minnoxide" for 5% off! Sure Things Logistics: https://www.surethinglogistics.net MORE BIGGER Turbo T-Shirts: https://www.minnoxide.com/products/more-bigger-t-shirt
In this week's episode, we'll learn more about how exogenous CD19 stimulation affects CAR T-cell persistence in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy; new algorithms that incorporate sequential rapid immune-assays, intended to improve diagnosis of heparin-induced thrombocytopenia, and resource-adaptive survival prediction models to help guide management of patients with chronic myelomonocytic leukemia.Featured Articles:Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALLSequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopeniaBLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
The revelation that shattered systems thinking: Replacing every combustion car with electric vehicles improves urban efficiency by only 6%—revealing why isolated optimizations fail in complex ecosystems.Dr. Parfait Atchadé from MIT Media Lab discovered this through quantum-enhanced urban modeling in Boston's Kendall Square. His breakthrough: humanized AI agents with emotional architectures that "live" in virtual cities for decades of compressed time, then vote on configurations—exposing the systematic failure of single-variable optimization. Paradigm Shifts:→ The Single-Solution Trap: Complex systems require the vast majority of improvements from interconnected changes—individual optimizations create illusion of progress while missing systemic impact→ Quantum Superposition Planning: Test multiple city configurations simultaneously rather than sequential scenarios—compress 40 years of urban experience into months of simulation→ Agents with Feelings: AI agents embedded with emotional models (joy, fear, anger, sadness) provide qualitative experience data impossible to capture from human stakeholders→ Portfolio Voting Revolution: Beyond binary decisions—split voting percentages across options like investment portfolios, enabling nuanced collective optimization→ Traditional systems modeling: Sequential scenario testing vs. Quantum approach: Parallel reality simulation with dramatic efficiency gainsThe Innovation: Humanized Agent-Based Modeling (h-ABM) creates digital beings with memory, perception, and emotional responses that navigate virtual systems, accumulating experiences and providing stakeholder insights traditional analytics cannot capture.Strategic Application: Any complex ecosystem requiring multi-stakeholder optimization—from organizational transformation to supply chain design—can leverage quantum-enhanced modeling with emotionally-intelligent agents.Strategic Reframe: The most adaptive ecosystems will shift from asking "How do we optimize individual components?" to understanding: "How do we architect systems where quantum-enhanced agents can help us reveal the hidden interdependencies that single-solution approaches systematically miss?"#EcosystemicFutures #QuantumComputing #SystemsThinking #UrbanPlanning #MIT #ComplexSystems #AgentBasedModelingGuest: Dr. Parfait Atchadé, Research Affiliate, MIT Media Lab | Strategic Business Officer, Lighthouse DIGHost: Marco Annunziata, Co-founder, Annunziata & Desai AdvisorsSeries Hosts: Vikram Shyam, Lead Futurist, NASA Glenn Research Center Dyan Finkhousen, Founder & CEO, Shoshin WorksEcosystemic Futures is provided by NASA Convergent Aeronautics Solutions Project in collaboration with Shoshin Works.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UMD865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 10, 2026.The Road Ahead for Enhanced Sequential Care in CLL—Updates With Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/HAZ865. CME/NCPD/IPCE credit will be available until July 17, 2026.The BCMA Playbook in Multiple Myeloma: Mastering Sequential Strategies With Bispecific Antibodies and CAR-T Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
© 2020-2026 Ivy Podcast Discovery LLC
